---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-25-000012"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T02:57:23.486242+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy

## Summary
- Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.
- RedHill contributes all Talicia assets; Cumberland handles distribution and records product sales.
- Talicia generated $8M net revenue in 2024; both companies equally share net revenues.
- Talicia is FDA-approved for H. pylori, patent protected through 2042, with QIDP exclusivity.
- Product has broad insurance coverage: 70% commercial, 60% government; CVS stocks at 1,700 pharmacies.

## SEC filing metadata
- accession: 0001087294-25-000012
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000012/0001087294-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000012/cpix-20251021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-25-000012
- JSON: https://secwatch.observer/filing/0001087294-25-000012.json
- Plain text: https://secwatch.observer/filing/0001087294-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.